Main Cause of Prostate Enlargement (Benign Prostatic Hyperplasia, BPH)

• Dihydrotestosterone (DHT): Testosterone is converted to DHT by the enzyme 5-alpha-reductase within prostatic stromal cells. DHT is a more potent androgen than testosterone and binds androgen receptors, stimulating growth factor release (e.g., FGF, TGF-beta) that drives proliferation of stromal and epithelial cells and inhibits cell death - leading to nodular enlargement over decades.
• Aging: BPH is strongly age-dependent - histologic evidence is present in about 20% of men by age 40, rising to 70% by age 60 and over 90% by age 80-90, though not all develop symptoms.
• Altered estrogen-to-androgen ratio: As men age, relative estrogen levels rise, which may sensitize prostate tissue to the growth-promoting effects of androgens.
• Stromal-epithelial signaling: Growth factors produced in the stroma act on epithelium in a paracrine fashion, a key mechanism in nodule formation.

• Metabolic syndrome, insulin resistance, and obesity are increasingly recognized as associated with BPH pathogenesis through inflammatory and metabolic pathways (PMID: 39488266, 2024 systematic review).
• Chronic prostatic inflammation.
• Genetic/familial predisposition.

Treatment for Age-Related Prostate Enlargement (BPH)

1. Watchful Waiting / Lifestyle Measures

• Reduce evening fluid intake, caffeine, and alcohol
• Timed voiding, avoid decongestants/antihistamines (worsen outlet obstruction)
• Weight loss and management of metabolic syndrome (increasingly linked to BPH progression)

2. Medical Therapy (moderate-severe symptoms)

• Relax prostatic and bladder-neck smooth muscle for rapid symptom relief (days)
• Do not shrink the gland - Katzung's Pharmacology notes doxazosin's class use is "Hypertension - benign prostatic hyperplasia," with first-dose orthostatic hypotension as a key adverse effect.

• Block conversion of testosterone to DHT, shrinking the gland over 6-12 months and reducing long-term risk of retention/surgery
• Best for larger prostates (>30-40 g)
• Per Lippincott's Pharmacology, finasteride's adverse effects include decreased libido, decreased ejaculation, and erectile dysfunction; it must not be handled by pregnant women due to teratogenic risk to a male fetus.

• Superior long-term reduction in symptom progression versus either drug alone, per Campbell-Walsh Urology's trial data on dutasteride/tamsulosin combinations.

• Improve LUTS, useful when erectile dysfunction coexists

3. Minimally Invasive Surgical Therapies (MIST)

• Prostatic urethral lift (UroLift), water vapor thermal therapy (Rezum), prostate artery embolization, Aquablation
• A 2024 systematic review in geriatric patients found these options have favorable safety profiles with fewer sexual side effects than TURP, though efficacy durability varies (PMID: 38656693).

4. Surgical Therapy (moderate-severe symptoms, retention, complications)

• Transurethral resection of prostate (TURP) remains the reference standard
• Laser enucleation (HoLEP), photoselective vaporization (PVP/GreenLight), open/robotic simple prostatectomy for very large glands
• A 2024 network meta-analysis comparing newer surgical interventions found differences in re-intervention rates across techniques, useful for counseling patients on durability of effect (PMID: 38600763).

Other/Adjunct

• Intraprostatic botulinum toxin injection has been studied as a minimally invasive option; a 2024 meta-analysis found some symptom benefit, though evidence quality is mixed and it's not yet standard of care (PMID: 35023701).

Practical approach by severity

Where this changes the plan

• Alpha-blocker + 5-alpha-reductase inhibitor (e.g., tamsulosin + dutasteride) - per Bailey & Love's Short Practice of Surgery, "combination therapy has a better outcome in glands bigger than 35 g," and your gland is more than double that threshold. The 5-ARI component is particularly important here because it actually shrinks glandular tissue and reduces future retention/surgery risk, whereas the alpha-blocker only relaxes smooth muscle for symptom relief.
• Response should be monitored over 6-12 months; if IPSS remains high, retention occurs, or there's recurrent hematuria/UTI/renal impairment, move to intervention.

• Standard TURP becomes technically harder and carries higher bleeding/fluid-absorption (TUR syndrome) risk once glands exceed roughly 80-100 g, because of longer resection time - Campbell-Walsh Urology notes "patients with large prostate volumes (e.g., >80 g) often offer technical challenges to the surgeon... larger prostates tend to fill most of the pelvic cavity making maneuverability more difficult."
• HoLEP (Holmium Laser Enucleation of the Prostate) is generally now the preferred size-independent option even for very large glands. Hinman's Atlas of Urologic Surgery notes it is "particularly advantageous for the treatment of large prostate, providing a minimally invasive alternative to open simple prostatectomy," with outcomes comparable to open surgery but shorter catheterization/hospital stay and less bleeding. Recent literature confirms HoLEP performs well even at very large volumes, though some series suggest slightly higher complexity/complication rates at the extreme end (>150-200 cc) (PMID: 39641120, 37716456).
• Open or robotic-assisted simple prostatectomy remains an option, particularly where laser enucleation expertise isn't available, but carries more blood loss and longer recovery than HoLEP. A 2023 comparative study found HoLEP, open, and robotic simple prostatectomy all achieve good symptom outcomes for large-gland BPH, with HoLEP generally showing shorter hospital stay and less blood loss (PMID: 36586427).
• GreenLight PVP (photoselective vaporization) and bipolar TURP are also feasible at experienced centers but data favor HoLEP for glands this large.
• Prostate artery embolization is an alternative for men who are poor surgical/anesthesia candidates, per Campbell-Walsh, though outcomes are generally less robust than resection/enucleation for symptom control.

Practical takeaway for your situation

1. If LUTS are mild-moderate and no complications (no retention, stones, renal impairment, recurrent bleeding/infection): trial combination alpha-blocker + 5-ARI therapy for 6-12 months.
2. If symptoms are severe, medical therapy fails, or complications are present: HoLEP is the best-supported minimally invasive surgical option for an 80g gland at a center with laser expertise; open/robotic simple prostatectomy is a solid alternative.
3. Age 61 alone is not a barrier to any of these options - fitness for anesthesia and comorbidities matter more than age itself at this stage.

Standard Dosing for BPH Medications

Alpha-blockers (symptom relief - pick one)

5-alpha-reductase inhibitors (shrink the gland - relevant given the 80g size)

Combination product

• Dutasteride 0.5 mg + Tamsulosin 0.4 mg once daily (marketed as a fixed-dose combination, e.g., Jalyn) - this is the combination Bailey & Love notes as superior for glands over 35 g, which fits an 80 g prostate well.

Adjunct (if erectile dysfunction coexists)

• Tadalafil 5 mg once daily (the low-dose daily regimen used for LUTS, distinct from the on-demand ED dose)

Important caveats

• These are standard adult starting/maintenance doses from major pharmacology and urology references, not a personalized prescription.
• The actual dose must be set by the prescribing physician based on renal function, liver function, blood pressure, concurrent medications (especially other antihypertensives, which compound alpha-blocker hypotension), and how the patient tolerates titration.
• Alpha-blockers need dose titration to avoid orthostatic hypotension, especially in a 61-year-old who may be on other BP medications.
• 5-ARIs take 6-12 months to show full effect on gland size and symptoms.
• I have not prescribed or verified this for you personally, this is reference information only. A urologist or physician should confirm the specific regimen and monitor PSA (5-ARIs roughly halve PSA levels, which needs to be accounted for when screening for prostate cancer) and liver/renal function as appropriate.

Why they're not directly linked

What urethral/bladder outlet obstruction actually does

When you might see both elevated together (indirect, not causal)

1. Urosepsis/severe UTI from obstruction - sepsis can cause "sepsis-associated cholestasis," an indirect systemic effect on the liver, elevating conjugated bilirubin. This is the most plausible clinical link if it exists.
2. Medication effects - some antibiotics used for urinary infections (e.g., trimethoprim/sulfamethoxazole) are noted in the Washington Manual as causing "cholestatic jaundice" and "obstructive uropathy" as two separate, unrelated side effects of the same drug - not one causing the other.
3. Coincidental liver/biliary disease - gallstones, hepatitis, or hemolysis occurring independently in the same patient.
4. Severe dehydration or multi-organ stress in advanced obstructive uropathy could stress the liver secondarily, but this is uncommon and nonspecific.

Bottom line

Interpreting this report

• Grade I: <20-25 g (normal/mildly enlarged)
• Grade II: ~20-40 g
• Grade III: ~40-60 g
• Grade IV: >60 g (markedly enlarged)

• No mass = no sonographically visible focal lesion suspicious for prostate cancer. Ultrasound isn't as sensitive as MRI for detecting early cancer, so this doesn't fully exclude malignancy, but it's a good sign, especially combined with symmetric, diffuse enlargement (typical of BPH rather than a focal cancerous nodule).
• No calcifications = no prostatic calculi, which are a common incidental finding (usually asymptomatic, sometimes linked to chronic inflammation) and not concerning on their own.

What this changes practically

1. This finding alone is not a diagnosis of BPH; it needs to be correlated with symptoms (IPSS), PSA, post-void residual, and renal function to decide the management path.
2. Given imaging shows no mass, a normal-range PSA would make BPH the most likely explanation for the enlargement rather than cancer, but PSA and DRE findings should still be reviewed by the treating urologist, particularly since PSA correlates with prostate volume regardless of cause.
3. For a gland this size, if symptoms are significant, combination therapy (alpha-blocker + 5-alpha-reductase inhibitor) remains reasonable first-line, and if surgery becomes necessary, HoLEP or simple prostatectomy are the size-appropriate options over standard TURP, as discussed previously.

Why standard TURP is not ideal here

Most suitable options for this gland size

• Considered essentially size-independent; performs well from moderate to very large glands (well beyond 81 g, including >150-200 g in experienced centers)
• Removes the entire adenoma (enucleation, not just resection), similar completeness to open surgery
• Advantages: less bleeding (safe even on anticoagulation), shorter catheterization time, shorter hospital stay, durable long-term results
• Main limitation: requires specific laser training/expertise, not available at every center

• Uses saline irrigation instead of hypotonic fluid, largely eliminating TUR syndrome risk, and can be extended to larger glands than traditional monopolar TURP
• A reasonable option if HoLEP expertise isn't locally available, though operative time and bleeding risk still rise with gland size
• Sometimes done in a staged fashion for very large glands

• Solid, time-tested option for large glands, especially where laser/advanced endoscopic equipment isn't available
• Complete removal of the enlarged adenoma through an abdominal (open) or robotic approach
• Trade-off: more blood loss and longer recovery than HoLEP, though robotic approach narrows that gap somewhat

• Feasible at this size in experienced hands, though data and outcomes are less robust than HoLEP for large glands

• Reserved for men who are poor candidates for anesthesia/surgery; less reliable symptom improvement than resection/enucleation, but avoids surgical risk entirely

Bottom line recommendation